TD Cowen Notes Shifting Positive Sentiment for Halozyme (HALO) Ahead of Q4 Earnings, 2026 Guidance

Group 1 - Halozyme Therapeutics Inc. is identified as a promising mid-cap growth stock, with TD Cowen raising its price target from $79 to $90 while maintaining a Buy rating [1] - Investor sentiment is shifting positively ahead of Q4 2025 earnings, with 2026 guidance being crucial for positioning in a sector-wide recovery [1][3] - A global collaboration and exclusive license agreement was announced between Takeda and Halozyme, granting Takeda access to Halozyme's ENHANZE drug-delivery technology for vedolizumab [2][3] Group 2 - The agreement allows Takeda to utilize Halozyme's recombinant human hyaluronidase PH20 enzyme to enhance the subcutaneous delivery of vedolizumab, aiming to improve treatment flexibility and reduce therapy management time [3] - Halozyme is a biopharmaceutical company focused on researching, developing, and commercializing proprietary enzymes and devices both in the US and internationally [4]